Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 rapid-response study of cAd3 Marburg vaccine in adults during a Marburg outbreak
PACTR202512762754420Phase 2Completed
- Sponsor
- Ministry of Health Ethiopia
- Start
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Marburg virus disease (MVD) (2 cohorts), sponsored by Ministry of Health Ethiopia. Primary endpoints: Serious adverse events, Solicited adverse events and 4 more. Started Dec 2025; status: completed.
02
Conditions
Marburg virus disease (MVD)
Beyond the preview
Go deeper on PACTR202512762754420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202512762754420.